TITLE

Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline

AUTHOR(S)
Miller, S. L.; Fenstermacher, E.; Bates, J.; Blacker, D.; Sperling, R. A.; Dickerson, B. C.
PUB. DATE
June 2008
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jun2008, Vol. 79 Issue 6, p630
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: To use functional MRI )fMRI) to investigate whether hippocampal activation during a memory task can predict cognitive decline in individuals with mild cognitive impairment (MCI). Methods: 25 older individuals with MCI performed a visual scene encoding task during fMRI scanning, and were followed clinically for at least 4 years after scanning. A hypothesis driven analysis of fMRI data was performed. First, fMRI data were analysed at the group level to identify the regions of the hippocampal formation that were engaged by this memory task. Parameter estimates of each subject's memory related hippocampal activation )% signal change) were extracted and were analysed with a linear regression model to determine whether hippocampal activation predicted the degree or rate of cognitive decline, as measured by change in Clinical Dementia Rating Sum-of-Boxes )CDR-SB). Results: Over 5.9 (1.2) years of follow-up after scanning, subjects varied widely in degree and rate of cognitive decline (change in CDR-SB ranged from 0 to 6, and the rate ranged from 0 to 1 CDR-SB unit/year). Greater hippocampal activation predicted greater degree and rate of subsequent cognitive decline )p<0.05). This finding was present even after controlling for baseline degree of impairment )CDR-SB), age, education and hippocampal volume, as well as gender and apolipoprotein E status. In addition, an exploratory whole brain analysis produced convergent results, demonstrating that the hippocampal formation was the only brain region where activation predicted cognitive decline. Conclusions: In individuals with MCI, greater memory task related hippocampal activation is predictive of a greater degree and rate of cognitive decline subsequent to scanning. fMRI may provide a physiological imaging biomarker useful for identifying the subgroup of MCI individuals at highest risk of cognitive decline for potential inclusion in disease modifying clinical trials.
ACCESSION #
32621928

 

Related Articles

  • Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. Wolf, Robert C; Gr�n, Georg; Sambataro, Fabio; Vasic, Nenad; Wolf, Nadine D; Thomann, Philipp A; Saft, Carsten; Landwehrmeyer, G Bernhard; Orth, Michael // Journal of Cerebral Blood Flow & Metabolism;Sep2011, Vol. 31 Issue 9, p1908 

    Magnetic resonance imaging (MRI) of the brain could be a powerful tool for discovering early biomarkers in clinically presymptomatic carriers of the Huntington's disease gene mutation (preHD). The aim of this study was to investigate the sensitivity of resting-state perfusion MRI in preHD and to...

  • Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Petkau, J.; Reingold, S. C.; Held, U.; Cutter, G. R.; Fleming, T. R.; Hughes, M. D.; Miller, D. H.; McFarland, H. F.; Wolinsky, J. S. // Multiple Sclerosis (13524585);Jul2008, Vol. 14 Issue 6, p770 

    Background Magnetic resonance imaging (MRI) of lesions in the brain may be the best current candidate for a surrogate biological marker of clinical outcomes in relapsing remitting multiple sclerosis (MS), based on its role as an objective indicator of disease pathology. No biological surrogate...

  • Imaging as Biomarkers. Adineh, Mehdi // Applied Clinical Trials;Jan2010 Supplement, p16 

    The article discusses the significance of medical imaging techniques as biomarkers in creating an efficient and affordable clinical trials in the U.S. It indicates that medical imaging is use in all phases of new drug development to guide the diagnosis, treatment, and management of disease....

  • Huntington's Biomarkers Found.  // Genomics & Proteomics;Sep2005, Vol. 5 Issue 7, p11 

    Reports on the identification of 12 genetic biomarkers that correlate with various stages of the disease by performing genome-wide expression profiling on the blood of individuals with and without Huntington's disease (HD). Reduction of the elevated messenger RNA in HD patients; Application of...

  • Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood. Mastrokolias, Anastasios; Ariyurek, Yavuz; Goeman, Jelle J; van Duijn, Erik; Roos, Raymund AC; van der Mast, Roos C; van Ommen, GertJan B; den Dunnen, Johan T; 't Hoen, Peter AC; van Roon-Mom, Willeke MC // European Journal of Human Genetics;Oct2015, Vol. 23 Issue 10, p1349 

    With several therapeutic approaches in development for Huntington's disease, there is a need for easily accessible biomarkers to monitor disease progression and therapy response. We performed next-generation sequencing-based transcriptome analysis of total RNA from peripheral blood of 91...

  • Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease. Herben-Dekker, Meike; Oostrom, Joost; Roos, Raymund; Jurgens, Caroline; Witjes-Ané, Marie-Noëlle; Kremer, Hubertus; Leenders, Klaus; Spikman, Jacoba // Journal of Neurology;Jul2014, Vol. 261 Issue 7, p1387 

    The clinical diagnosis of Huntington's disease (HD) is based on the motor symptoms, although these can be preceded by cognitive and behavioral changes. Biomarker studies have shown that structural imaging modalities are useful biomarkers of HD onset, while functional imaging measures have been...

  • Poster 12: A Metabolic Network Associated with the Progression of Preclinical Huntington's Disease: Application of the Ordinal Trends Analysis to a Longitudinal PET Study Tang, C.; Feigin, A.; Poston, K.L.; Ma, Y.; Guttman, M.; Paulsen, J.S.; Dhawan, V.; Eidelberg, D. // Neurotherapeutics;Jan2009, Vol. 6 Issue 1, p207 

    Objective: To characterize longitudinal changes in metabolic network activity during phenoconversion in preclinical Huntington''s disease (pHD) patients. Background: Metabolic changes accompanying phenoconversion in HD are not well understood. The ordinal trends (OrT) model is a novel...

  • Pharmacological Management of Huntington's Disease: An Evidence- Based Review. Bonelli, Raphael M.; Wenning, Gregor K. // Current Pharmaceutical Design;Jul2006, Vol. 12 Issue 21, p2701 

    Introduction: Despite the increasing body of published reports on pharmacological interventions in Huntington's disease (HD), an evidence based review (EBR) of treatment studies has not yet been published. Method: Systematic literature searches were done using Medline (1965 - August 2005), the...

  • Keynote address—Huntington's Advocacy: Why I Care Roberson, Judy // Neurotherapeutics;Jan2010, Vol. 7 Issue 1, p135 

    After nearly twenty years as an HD advocate, this widow at age 48 and mother of four tells her family''s story. Although she had hoped that her efforts would save her husband, now her focus is on saving her children who are at-risk. The many years of leadership with the HDSA Northern California...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics